Neuronex

Neuronex is a pharmaceutical company focused on developing innovative therapies for neurological disorders, enhancing patient mobility and quality of life through advanced medication delivery systems. Neuronex specializes in developing neurological therapies and was acquired by Acorda Therapeutics in February 2012. The company operates from Morrisville, US. The acquisition marks a significant strategic pivot, allowing Neuronex to leverage Acorda’s resources and market presence.

Acorda Therapeutics, Inc. , founded by individuals with extensive backgrounds in the pharmaceutical industry, has focused on advancing treatment options in neurology. Neuronex offers specialized products and services aimed at addressing neurological disorders. Its core product, AMPYRA® (dalfampridine), enhances mobility in multiple sclerosis patients, while INBRIJA® (levodopa inhalation powder) addresses off episodes in Parkinson’s disease patients.

Additionally, the ARCUS® technology facilitates improved medication delivery, targeting healthcare providers and pharmacies primarily in the United States and selected international markets. Neuronex generates revenue through direct sales of its pharmaceutical products to healthcare providers and pharmacies. The company employs a business-to-business (B2B) model collaborating with wholesalers and distributors to ensure product market availability. Pricing for its products is based on therapeutic value and market demand, influenced by reimbursement rates and insurance coverage, impacting patient access to treatments.

Neuronex aims to expand its product offerings and market presence. Following its acquisition by Acorda Therapeutics, the company is expected to develop new therapies targeting previously unmet needs in the neurological space. The recent acquisition will also provide the necessary funding to support these initiatives, with strategic plans to expand its geographic reach into additional international markets in the coming years.